NASDAQ:NVUS - Novus Therapeutics Stock Price, Forecast & News

Novus Therapeutics trades on the NASDAQ under the ticker symbol "NVUS."

Novus Therapeutics Inc (NASDAQ:NVUS) issued its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.19. View Novus Therapeutics' Earnings History.

Novus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Novus Therapeutics.

2 brokerages have issued 12-month target prices for Novus Therapeutics' shares. Their forecasts range from $2.00 to $10.00. On average, they expect Novus Therapeutics' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,100.2% from the stock's current price. View Analyst Price Targets for Novus Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novus Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novus Therapeutics.

Headlines about NVUS stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novus Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Novus Therapeutics.

Novus Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 19,500 shares, a decrease of 67.5% from the January 15th total of 60,000 shares. Based on an average trading volume of 125,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are short sold. View Novus Therapeutics' Current Options Chain.

Some companies that are related to Novus Therapeutics include Seelos Therapeutics (SEEL), Kazia Therapeutics (KZIA), AzurRx BioPharma (AZRX), China SXT Pharmaceuticals (SXTC), Sophiris Bio (SPHS), AEterna Zentaris (AEZS), Unum Therapeutics (UMRX), Provectus Biopharmaceuticals (PVCT), Ceapro (CRPOF), Aptevo Therapeutics (APVO), Dare Bioscience (DARE), Guardion Health Sciences (GHSI), ProPhase Labs (PRPH), Aileron Therapeutics (ALRN) and OHR Pharmaceutical (OHRP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Rigel Pharmaceuticals (RIGL), T2 Biosystems (TTOO) and Tetraphase Pharmaceuticals (TTPH).

Novus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.51%). Company insiders that own Novus Therapeutics stock include Catherine C Turkel, Erez Chimovits, Gregory J Flesher, Jon Kuwahara and Lifesci Index Partners Llc. View Institutional Ownership Trends for Novus Therapeutics.

NVUS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Novus Therapeutics stock in the last two years include Catherine C Turkel and Erez Chimovits. View Insider Buying and Selling for Novus Therapeutics.

Shares of NVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVUS stock can currently be purchased for approximately $0.50.

Novus Therapeutics has a market capitalization of $6.48 million. The biopharmaceutical company earns $-14,060,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. View Additional Information About Novus Therapeutics.

The official website for Novus Therapeutics is http://novustherapeutics.com/.

Novus Therapeutics' mailing address is 19900 MACARTHUR BLVD. SUITE 550, IRVINE CA, 92612. The biopharmaceutical company can be reached via phone at 949-238-8090 or via email at [email protected]